论文信息 - A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. - 字舞流文

A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

J. Sosman | C. Drake | D. Smith | M. Sznol | J. Wigginton | G. Kollia | D. Feltquate | D. McDermott | J. Powderly | A. Gupta